95TiP - A Phase 3, Randomised, Double-Blind, Placebo-Controlled, International Study of Medi4736 in Patients with Locally Advanced, Unresectable, Stage 3 Nsclc Who Have not Progressed Following Platinum-Based, Concurrent Chemoradiation Therapy (PACIFIC)

Abstract

Background: Standard treatment for locally advanced NSCLC has consisted of concurrent radiation with a platinum-based chemotherapy. Nonetheless, the majority of patients ultimately die due to cancer recurrence. Chemotherapy and radiotherapy upregulate the expression of programmed cell death ligand-1 (PD-L1), an inhibitory checkpoint that cancer cells harness to evade antitumour immune responses. MEDI4736 is a human IgG1 kappa mAb that blocks PD-L1 binding to its partner receptor; it is engineered to avoid antibody dependent cell-mediated cytotoxicity.